Proscia®, a leading pathology AI company, has introduced Proscia Aperture™, a breakthrough precision medicine platform designed to automatically identify eligible patients at the point of diagnosis. By transforming routine pathology data into real-time intelligence, Aperture empowers biopharmaceutical companies to speed up therapy development and expand patient access to innovative treatments.
Currently, fewer than one in ten cancer patients enroll in clinical trials, leaving many without access to potentially life-saving therapies. Diagnostic laboratories—positioned at the intersection of pathology, molecular biology, and clinical insights—can help bridge this divide.
With the rise of digital pathology, each tissue image now carries a detailed disease profile. However, these rich data sources have remained underutilized in drug development, despite growing investment in precision medicine strategies.
“One of the hardest realities in precision medicine is that too many patients never have the chance to benefit from breakthrough therapies,” said Suso Platero, former Chief Scientific Officer at Discovery Life Sciences. “Pathology data holds the keys to changing this. By unlocking insights at the moment of diagnosis, we can ensure that scientists have the understanding they need to bring the next treatments to market while giving patients a greater opportunity to access them.”
Through Proscia’s Concentriq® platform, Aperture is connected to a global lab network expected to deliver more than 8 million diagnoses this year. Its AI analyzes digital tissue images, molecular data, and clinical records to:
Generate evidence for regulatory submissions
Support companion diagnostic development
Inform label expansions and payer negotiations
Surface eligible clinical trial candidates in real time
The system also scales intelligence through Proscia’s vast real-world dataset of over 12 million tissue images linked with genomic and clinical records. Stringent governance and de-identification processes ensure patient privacy remains protected.
"Diagnostic laboratories are under growing pressure to do more with fewer resources, even as demand for precision medicine continues to rise,” said Nina Green, Vice President and General Manager, Clinical Diagnostics Division at Agilent Technologies. “Aperture opens an avenue with the potential to advance clinical trials, companion diagnostic development, and broaden patient access.”
For laboratories, Aperture not only enhances diagnostic accuracy but also creates new opportunities to:
Expand service offerings
Strengthen competitive differentiation
Drive research collaborations
Overcome challenges of shrinking margins and workforce shortages
“Aperture shows the world that pathology is no longer the end of the diagnostic journey but the driver of what comes next for patients,” said David West, CEO of Proscia. “By unlocking insights at the moment of diagnosis, we unite research and care, making the future of pathology a reality.”
Proscia will unveil Aperture at Access25, its virtual event scheduled for October 28, highlighting its potential to reshape how pathology contributes to precision medicine worldwide.